Peter De Porre

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Matthew R. Smith, Karim Fizazi et al. · The Lancet Oncology · 2015 · 1.3K citations

Urology, Oncology, Prednisone Versus Placebo +7

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Apalutamide and Overall Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · European Urology · 2020 · 277 citations · Full text

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial

Kim N., Andrew Protheroe, Gaetano Facchini et al. · The Lancet Oncology · 2018 · 163 citations

Patient-reported Outcomes, Urology, Genitourinary Cancer +8